miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome
journal contributionposted on 14.06.2021, 15:50 authored by Qistina Pilson, Siobhan Smith, Caroline A Jefferies, Joan Ni Gabhann-DromgooleJoan Ni Gabhann-Dromgoole, Conor MurphyConor Murphy
In primary Sjögren's syndrome (pSS) the exocrine glands become infiltrated with lymphocytes instigating severe damage to the salivary and lacrimal glands causing dry eyes and dry mouth. Previous investigations have suggested that dysregulated localized and systemic inflammation contributes to the development and pathogenesis of pSS. A miR microarray performed in primary human conjunctival epithelial cells (PECs) demonstrated significant differences in miR expression at the ocular surface between pSS patients and healthy controls. MicroRNA-744-5p (miR-744-5p) was identified as being of particular interest, as its top predicted target is Pellino3 (PELI3), a known negative regulator of inflammation. Validation studies confirmed that miR-744-5p expression is significantly increased in PECs from pSS patients, whilst PELI3 was significantly reduced. We validated the miR-744 binding site in the 3' untranslated region (UTR) of PELI3 and demonstrated that increasing PELI3 levels with a miR-744-5p antagomir in an inflammatory environment resulted in reduced levels of IFN dependent chemokines Rantes (CCL5) and CXCL10. These results reveal a novel role for miR-744-5p in mediating ocular inflammation via Pellino3 expression in pSS patients and suggest that miR-744-5p may be a potential therapeutic target for the management of severe dry eye disease and ocular inflammation in pSS patients.
Health Research Board
Royal Victoria Eye and Ear Hospital Research Foundation through the Medical Research Charities Group.
CommentsThe original article is available at https://www.nature.com
Published CitationPilson Q, Smith S, Jefferies CA, Ní Gabhann-Dromgoole J, Murphy CC. miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome. Sci Rep. 2020;10(1):7484.
Publication Date4 May 2020
- School of Pharmacy and Biomolecular Sciences
- Surgical Science and Practice
- Biomaterials and Regenerative Medicine
- Immunity, Infection and Inflammation
PublisherNature Publishing Group
- Published Version (Version of Record)